+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of de novo and recurrent membranous nephropathy in renal transplant patients



Treatment of de novo and recurrent membranous nephropathy in renal transplant patients



Seminars in Nephrology 23(4): 392-399



Membranous nephropathy (MN) is one of the common glomerular diseases diagnosed in transplanted kidneys. The exact impact of posttransplantation MN on the risk for graft loss and long-term graft outcome is not defined clearly. In recent reports, it has emerged as the third most frequent glomerulonephritis (de novo or recurrent) associated with renal allograft loss. Most cases of posttransplantation MN are thought to be idiopathic but cases associated with established secondary causes also have been reported. Patients can present with varying degrees of proteinuria and graft dysfunction. Risk factors that predict a poor outcome are not well established and unlike MN in the native kidneys, spontaneous remission is rare. Patients should be evaluated carefully for complications associated with nephrotic syndrome or graft dysfunction and managed accordingly. The beneficial effects of steroids, cyclosporine, mycophenolate mofetil, cyclophosphamide, chlorambucil, or other agents have not been validated. The role of specific treatments in cases of secondary MN is uncertain. Retransplantation is a reasonable option for patients who develop graft failure secondary to MN.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050838021

Download citation: RISBibTeXText

PMID: 12923728

DOI: 10.1016/s0270-9295(03)00057-3


Related references

De novo and recurrent membranous nephropathy in renal allografts. Kidney International 37(1): 187, 1990

Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. American Journal of Transplantation 6(12): 3017-3021, 2006

An early case of de novo membranous nephropathy in a renal transplant patient. Transplantation Proceedings 34(1): 364, 2002

Concurrence of de novo membranous glomerulonephritis and recurrent IgA nephropathy in a renal allograft. Clinical Nephrology 42(4): 269-272, 1994

Recurrent immunoglobulin A nephropathy complicated with de novo membranous glomerulonephritis in renal allografts. Transplantation Proceedings 34(8): 3117-3118, 2002

Membranous glomerulonephritis in transplant kidneys: recurrent or de novo disease in four patients. Clinical Nephrology 15(3): 154-163, 1981

A case of recurrent IgA nephropathy complicated with de novo membranous nephropathy in the graft. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 73(12): 1856-1860, 1984

Complement c 5b 9 complex is found in subepithelial deposits of stage i idiopathic membranous nephropathy but not of stage i de novo membranous nephropathy and toxic induced membranous nephropathy. Kidney International 26(4): 633, 1984

De novo membranous nephropathy in human renal allografts: report of nine patients. Kidney International 22(2): 177-183, 1982

De novo postallogeneic hematopoietic stem cell transplant membranous nephropathy. Experimental and Clinical Transplantation 11(1): 75-78, 2013

Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. American Journal of Transplantation 11(10): 2144-2152, 2011

A complex microdeletion 17q12 phenotype in a patient with recurrent de novo membranous nephropathy. BMC Nephrology 13(1): 27, 2012

A complex microdeletion 17q12 phenotype in a patient with recurrent de novo membranous nephropathy. Bmc Nephrology 13: 27, 2012

Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab. Ndt Plus 2(5): 395-397, 2009

Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. Clinical Nephrology 26(4): 203-208, 1986